title: Biochemical effect of intravenous arginine butyrate in X-linked adrenoleukodystrophy.
abstract: OBJECTIVE
  To determine the biochemical and clinical effects of intravenous arginine butyrate in X-linked Adrenoleukodystrophy (X-ALD).
  
  
  METHODS
  Arginine butyrate was intravenously infused over a 4-month period in a patient with the rapid cerebral form of X-ALD. Very long chain fatty acids (VLCFA), complete blood counts, and serum chemistries were monitored, and serial MRI of the brain and clinical neurologic examinations were performed.
  
  
  RESULTS
  All blood chemical and hematologic values remained within the normal range for age throughout the therapy. After completion of the first day of infusion, the C 26:0 value fell from 1.01 microg/mL to 0.445 microg/mL, which is below the mean value for an X-ALD heterozygote. Throughout the remainder of the trial, all C26:0 levels fell below the mean -1 SD for X-ALD hemizygotes (mean, 1.18 microg/mL, 1 SD = 0.53), ranging from 0.321 to 0.565 microg/mL. Despite reduction of the plasma VLCFA, the patient continued to deteriorate neurologically.
  
  
  CONCLUSIONS
  Intravenous arginine butyrate resulted in a rapid decrease in plasma VLCFA but no effect on the neurologic progression of the disease in this patient. Additional studies are needed to determine minimum effective dosage and interval, what proportion of patients respond, and whether the agent can prevent neurologic degeneration.
authors.affiliation: Department of Human Genetics, Mount Sinai School of Medicine, New York City, New York, USA.
authors.forename: Margaret M
authors.initials: MM
authors.lastname: McGovern
authors.forename: Melissa P
authors.initials: MP
authors.lastname: Wasserstein
authors.forename: Alan
authors.initials: A
authors.lastname: Aron
authors.forename: Susan P
authors.initials: SP
authors.lastname: Perrine
mesh_terms: D000326:Adrenoleukodystrophy / Q000097:blood / Q000188:drug therapy*; D001120:Arginine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D002087:Butyrates / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D003066:Coenzyme A Ligases / Q000097:blood; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D012097:Repressor Proteins; D029701:Saccharomyces cerevisiae Proteins; D000098859:Long-Chain-Fatty-Acid-CoA Ligase
chemical_list: D002087:Butyrates; D012097:Repressor Proteins; D029701:Saccharomyces cerevisiae Proteins; D001120:Arginine; D003066:Coenzyme A Ligases; C090799:FAA2 protein, S cerevisiae; D000098859:Long-Chain-Fatty-Acid-CoA Ligase; C033018:arginine butyrate